Fasiglifam，TAK-875

Non chimik:

(S)-2-(6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3 -dihydrobenzofuran-3-yl) asid acetic

Kòd SMILES:

O=C(O)C[C@@H]1COC2=CC(OCC3=CC(C4=C(C)C=C(OCCCS(=O)(C)=O)C=C4C)=CC=C3 )=CC=C12

Kòd InChi:

InChI=1S/C29H32O7S/c1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21( 14-22)17-35-24-8-9-2 6-23(15-28(30)31)18-36-27(26)16-24/h4,6-9,12-14,16,23H,5,10-11,15,17-18H2, 1-3H3,(H,30,31)/t23-/m1/s1

InChi kle:

BZCALJIHZVNMGJ-HSZRJFAPSA-N

Mot:

1000413-72-8；CAS:1000413-72-8；CAS:1000413-72-8；TAK875；TAK-875；TAK 875；Fasiglifam

Solibilite:Soluble nan DMSO, pa nan dlo

Depo:0 - 4 C pou kout tèm (jou a semèn), oswa -20 C pou long tèm (mwa).

Deskripsyon:

Fasiglifam (TAK-875) se yon agonist GPR40 efikas, oral ak selektif.

Sib: GPR40 agonist